Cardiovascular management of marfan syndrome in the young
Marfan syndrome is an autosomal-dominant disorder of connective tissue resulting from a mutation in the fibrillin gene. Manifestations of the disorder primarily affect the skeletal, cardiovascular, and ocular systems. The phenotypic manifestations of this disorder can be quite variable. The major cause of morbidity and mortality in this patient population is the cardiovascular manifestations of the disorder: aortic root dilation and dissection. Individuals with this disorder are at risk for catastrophic cardiovascular events, most often as a result of aortic dissection. Although the incidence of dissection in childhood is exceedingly low, the background of a progressively dilating aortic root appears to be the major factor contributing to this risk in adulthood. Therefore, it is beneficial to identify affected individuals as early as possible to institute lifestyle changes and medical therapy in an effort to enhance their long-term outcome. Familial screening, once a case has been identified, and consideration of genetic screening of an affected family may also be helpful. Medical therapy with β blockers, calcium channel blockers, and/or angiotensin inhibitors has been shown to be somewhat effective in slowing the rate of growth of the aorta. Exciting new data suggest that angiotensin II receptor antagonists may provide an even greater degree of protection from aortic dilatation in this population. Despite medical therapy, patients with Marfan syndrome do have progressive dilatation of their aortic root. The risk of aortic dissection increases with increasing size of the aorta. Prophylactic surgical techniques have been successful in reducing the morbidity and mortality associated with aortic dissection, resulting in a longer average life span in this patient population.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Pyeritz RE: Marfan syndrome and other disorders of fibrillin. In Principles and Practice of Medical Genetics, edn 3. Edited by Rimoin DL, et al. New York: Churchill Livingstone; 1997:1027–1066.Google Scholar
- 6.Pyreitz RE: Effectiveness of beta-adrenergic blockade in the Marfan syndrome: experience over 10 years. Am J Med Genet 1989, 32:245.Google Scholar
- 10.Health supervision for children with Marfan syndrome. American Academy of Pediatrics Committee on Genetics [no authors listed]. Pediatrics 1996, 98:978–982.Google Scholar
- 11.National Marfan Foundation. Available at http://www.marfan.org/nmf/. Accessed April 2006.Google Scholar
- 16.Dietz HC, Pyeritz RE: Marfan syndrome and related disorders. In The Metabolic and Molecular Bases of Inherited Disease, edn 8. Edited by Scriver CR, et al. New York: McGraw-Hill; 2000:5287–5311.Google Scholar
- 19.Milewicz DM, Dietz HC, Miller DC: Treatment of aortic disease in patients with Marfan Syndrome. Circulation 2005, 111:e150-e157. A concise, thorough review of the Marfan syndrome. The focus is predominantly on the cardiovascular manifestations of Marfan syndrome and their medical and surgical management.PubMedCrossRefGoogle Scholar
- 22.Dietz HC, Loeys B, Carta L, Ramirez F: Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet Part C Semin Med Genet 2005, 139:4–9.Google Scholar
- 23.Judge DP, Dietz HC: Marfan’s syndrome. Lancet 2005, 366:1965–1976. An excellent review of the Marfan syndrome. Additional data include a listing of other syndromes that present with similar phenotypic characteristics to the Marfan syndrome. Also, a discussion of the most current genetic studies leading to potential advances in medical therapeutics is presented.PubMedCrossRefGoogle Scholar